This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|July 2, 2020
Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility
Author(s)BioPharm International Editors
The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.
Advertisement
US-based Grand River Aseptic Manufacturing (GRAM), a parenteral contract, development, and manufacturing organization (CDMO), has completed a $60-million expansion project in Grand Rapids, MI, and recently began occupancy at the site, the company announced in a June 30, 2020 press release.
With the expansion completed, the CDMO opened its new large-scale aseptic fill/finish facility in Grand Rapids, which more than triples its existing footprint. The added capacity, updated technologies, and state-of-the-art equipment provide flexible solutions for complex sterile injectables.
The new facility is part of the GRAM campus and is the third fill/finish facility for the company, giving it more than 100,000 ft2 of dedicated space that features:
- A fully integrated, high-speed Bausch+Ströbel filling line
- SKAN isolators and an IMA lyophilizer auto-loader
- Grade C cleanroom and formulation suites.
Advertisement
Related to this article
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5